ExpreS2ion publishes filmed scientific interview on the cVLP COVID-19 vaccine development
ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces that a filmed scientific talk on the development of the cVLP COVID-19 vaccine has been published on the company’s website. The video features Dr. Max M Søgaard from ExpreS2ion and Dr. Ali Salanti from ExpreS2ion’s joint venture and development partner AdaptVac.
In the interview, Drs. Max M Søgaard and Ali Salanti talk about the rapid development process of the cVLP COVID-19 vaccine, and how it was made possible through a great collaborative effort between several industry entities and financiers. They also discuss the possibility of utilising their experiences from the cVLP COVID-19 vaccine project to speed up the development process of other pipeline projects.
The video can be viewed by following this link to ExpreS2ion’s website.
This informative scientific interview was produced by cell counting and analysis company Chemometec, and it is published on ExpreS2ion’s website with their permission.
Certified Adviser
Svensk Kapitalmarknadsgranskning AB
Telefon: +46 11 32 30 732
E-post: ca@skmg.se
For further information about ExpreS2ion Biotech Holding AB, please contact:
Bent U. Frandsen, CEO
Telephone: +45 4256 6869
E-mail: buf@expres2ionbio.com
About ExpreS2ion
ExpreS2ion Biotechnologies ApS is a fully owned Danish subsidiary of ExpreS2ion Biotech Holding AB with company register number 559033-3729. ExpreS2ion has developed a unique technology platform, ExpreS2, for fast and efficient non-clinical development and production of complex proteins for new vaccines and diagnostics. ExpreS2 is regulatorily validated for clinical supply. The platform includes functionally modified glycosylation variants for enhanced immunogenicity and pharmacokinetics. Since 2010, the Company has produced more than 300 proteins and 40 virus-like particles (VLPs) in collaboration with leading research institutions and companies. Since 2017, ExpreS2ion develops novel VLP based vaccines through its joint venture AdaptVac ApS. For additional information, please visit www.expres2ionbio.com and www.adaptvac.com.
Tags:
